Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers

Psycho-Oncology

Volumn 21, Issue 7, 2012, Pages 745-753

  Oñate Ocaña, Luis F ^a   Velázquez Monroy, Natalia ^a   Vázquez, Luis ^a   Espinosa Mireles De Villafranca, Pablo ^a   Núñez Rosas, Elvia ^a   Ovando Lezama, Maira ^a   Vilar Compte, Diana ^a   García Hubard, Gabriela ^b   Carrillo, José F ^a   Blazeby, Jane M ^c   Aiello Crocifoglio, Vincenzo ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

adenocarcinoma; EORTC; esophageal neoplasm; health related quality of life; stomach neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVOR; CONTROLLED STUDY; DISCRIMINANT VALIDITY; ESOPHAGOGASTRIC JUNCTION CARCINOMA; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH CANCER; TEST RETEST RELIABILITY; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HEALTH STATUS; HUMANS; LANGUAGE; MALE; MEXICO; MIDDLE AGED; PALLIATIVE CARE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; STOMACH NEOPLASMS; SURVIVORS; TRANSLATIONS; YOUNG ADULT;

EID: 84861729100     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1974     Document Type: Article

References (32)

1. Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH,. Gastric cancer. Lancet 2009; 374 (9688): 477-490.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer: Lyon, France, 2010. Available from:.
3. Oñate-Ocaña LF,. Gastric cancer in Mexico. Gastric Cancer 2001; 4: 162-164. (Pubitemid 33123479)
4. Oñate-Ocaña LF, Milán-Revollo G, Aiello-Crocifoglio V, et al,. Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico. Ann Surg Oncol 2007; 14: 1439-1448. (Pubitemid 46536808)
5. DeMeester SR,. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006; 13: 12-30.
6. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR,. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513. (Pubitemid 23033424)
7. Hansen S, Wiig JN, Giercksky KE, Tretli S,. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340-344. (Pubitemid 27224293)
8. Moller H,. Incidence of cancer of oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1992; 1: 159-164.
9. Harrison SL, Goldacre MJ, Seagroatt V,. Trends in registered incidence of oesophageal and stomach cancer in the Oxford region, 1974-88. Eur J Cancer Prev 1992; 1: 271-274.
10. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J,. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006; 24: 3178-3186. (Pubitemid 46646225)
11. Aaronson NK, Ahmedzai S, Bergman B, et al,. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
12. Blazeby JM, Conroy T, Hammerlid E, et al,. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003; 39: 1384-1394. (Pubitemid 36773781)
13. Blazeby JM, Conroy T, Bottomley A, et al,. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004; 40: 2260-2268. (Pubitemid 39348876)
14. Lagergren P, Fayers P, Conroy T, et al,. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 2007; 43: 2066-2073. (Pubitemid 47380365)
15. Ajani JA, Rodríguez W, Bodoky G, et al,. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
16. Macdonald JS, Smalley SR, Benedetti J, et al,. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
17. Cunningham D, Allum WH, Stenning SP, et al,. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
18. Oñate-Ocaña LF, Alcántara-Pilar A, Vilar-Compte D, et al,. Validation of the Mexican Spanish version of the EORTC C30 and STO22 questionnaires for the evaluation of health-related quality of life in patients with gastric cancer. Ann Surg Oncol 2009; 16: 88-95.
19. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM,. American Joint Committee on Cancer. AJCC Cancer Staging Manual (6th edn). Springer: New York, 2002.
20. Siewert JR, Stein HJ,. Adenocarcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis Esophagus 1996; 9: 173-182. (Pubitemid 26264246)
21. Koller M, Aaronson NK, Blazeby JM, et al,. Translation procedures for standardized quality of life questionnaires: The European Organization for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 2007; 43: 1810-1820. (Pubitemid 47238253)
22. Fayers PM, Aaronson NK, Bjordal K, et al,. The EORTC QLQ-C30 Scoring Manual (3rd edn). European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2001.
23. Blazeby JM,. Scoring Procedure for the EORTC QLQ-OG25. European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2010.
24. Tabachnik BJ, Fidell LS,. Using Multivariate Statistics. Harper & Row: London, 1993.
25. United States Census Bureau. Population Profile of the United States. Available from: http://www.census.gov/population/www/pop-profile/natproj.html (accessed 25 January 2010).
26. Scott NW, Fayers PM, Aaronson NK, et al,. The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. J Clin Epidemiol 2008; 61: 788-795.
27. Pagano IS, Gotay CC,. Ethnic differential item functioning in the assessment of quality of life in cancer patients. Health Qual Life Outcomes 2005; 3: 45-60.
28. McNair AGK, Brookes ST, Davis CR, Argyropoulos M, Blazeby JM,. Communicating the results of randomized clinical trials: do patients understand multidimensional patient-reported outcomes? J Clin Oncol 2010; 28: 738-743.
29. Park SE, Lee WK, Chung M, et al,. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol 2006; 57: 289-294.
30. Kim YW, Baik YH, Yun YH, et al,. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008; 248: 721-727.
31. Quinten C, Coens C, Mauer M, et al,. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10: 865-871.
32. Djärv T, Metcalfe C, Avery KN, Lagergren P, Blazeby JM,. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. J Clin Oncol 2010; 28: 1666-1670.